Gwen Lapham, PhD, MPH, MSW, joined Kaiser Permanente Washington Health Research Institute (KPWHRI) in 2013 as an addictions health services researcher. Since then, she has capitalized on her prior social work and health services training to do impactful research on evidence-based primary care for unhealthy substance use, including alcohol, cannabis, and opioids. She has recently begun making strides in understanding cannabis use among primary care patients, including medical use and use among prenatal women.
Dr. Lapham recently completed the CATALyST K12 Washington Learning Health System Program funded by the Agency for Healthcare Research and Quality and the Patient-Centered Outcomes Research Institute. In the program, she partnered with Kaiser Permanente Washington health system leaders and with KPWHRI’s Center for Accelerating Care Transformation to address gaps in the quality of behavioral health care for children and adolescents by developing and testing an integrated approach to adolescent mental health. She expects this work to lead to new evidence for effective implementation of adolescent mental health integrated in primary care.
She is also a co-investigator of the Primary Care Opioid Use Disorders Treatment, or PROUD trial, a pragmatic implementation trial of nurse care management for treatment of opioid use disorders in primary care, as well as the Health Systems node of the National Institute on Drug Abuse Clinical Trials Network. Dr. Lapham’s research projects specific to cannabis include:
Prior to working at KPWHRI, Dr. Lapham focused on qualitative and quantitative evaluation of preventive alcohol interventions in medical settings at the Veterans Health Administration in Seattle.
Implementation research; quality measurement
Screening and brief intervention; mental health quality measurement
Prevention and treatment
The SPARC trial successfully implemented behavioral health care into primary care. On our website, you can access tools for behavioral health integration, as well as frequently asked questions and publications.
Carrell DS, Cronkite DJ, Shea M, Oliver M, Luce C, Matson TE, Bobb JF, Hsu C, Binswanger IA, Browne KC, Saxon AJ, McCormack J, Jelstrom E, Ghitza UE, Campbell CI, Bradley KA, Lapham GT Clinical documentation of patient-reported medical cannabis use in primary care: Toward scalable extraction using natural language processing methods 2022 Jan;43(1):917-924. doi: 10.1080/08897077.2021.1986767. PubMed
Matson TE, Bradley KA, Lapham GT Self-reported Practices of Frontline Cannabis Dispensary Workers and the Implications for Clinicians 2021 Sep;4(9):e2125262. doi: 10.1001/jamanetworkopen.2021.25262. Epub 2021-09-01. PubMed
Matson TE, Carrell DS, Bobb JF, Cronkite DJ, Oliver MM, Luce C, Ghitza UE, Hsu CW, Campbell CI, Browne KC, Binswanger IA, Saxon AJ, Bradley KA, Lapham GT Prevalence of Medical Cannabis Use and Associated Health Conditions Documented in Electronic Health Records Among Primary Care Patients in Washington State 2021 May 3;4(5):e219375. doi: 10.1001/jamanetworkopen.2021.9375. Epub 2021-05-03. PubMed
Tsui JI, Akosile MA, Lapham GT, Boudreau DM, Johnson EA, Bobb JF, Binswanger IA, Yarborough BJH, Glass JE, Rossom RC, Murphy MT, Cunningham CO, Arnsten JH, Thakral M, Saxon AJ, Merrill JO, Samet JH, Bart GB, Campbell CI, Loree AM, Silva A, Stotts AL, Ahmedani B, Braciszewski JM, Hechter RC, Northrup TF, Horigian VE, Bradley KA Prevalence and Medication Treatment of Opioid Use Disorder Among Primary Care Patients with Hepatitis C and HIV 2021 Apr;36(4):930-937. doi: 10.1007/s11606-020-06389-7. Epub 2021-02-10. PubMed
Campbell CI, Saxon AJ, Boudreau DM, Wartko PD, Bobb JF, Lee AK, Matthews AG, McCormack J, Liu DS, Addis M, Altschuler A, Samet JH, LaBelle CT, Arnsten J, Caldeiro RM, Borst DT, Stotts AL, Braciszewski JM, Szapocznik J, Bart G, Schwartz RP, McNeely J, Liebschutz JM, Tsui JI, Merrill JO, Glass JE, Lapham GT, Murphy SM, Weinstein ZM, Yarborough BJH, Bradley KA PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment 2021 Jan 31;16(1):9. doi: 10.1186/s13722-021-00218-w. Epub 2021-01-31. PubMed
Williams EC, McGinnis KA, Rubinsky AD, Matson TE, Bobb JF, Lapham GT, Edelman EJ, Satre DD, Catz SL, Richards JE, Bryant KJ, Marshall BDL, Kraemer KL, Crystal S, Gordon AJ, Skanderson M, Fiellin DA, Justice AC, Bradley KA Alcohol Use and Antiretroviral Adherence Among Patients Living with HIV: Is Change in Alcohol Use Associated with Change in Adherence? 2021 Jan;25(1):203-214. doi: 10.1007/s10461-020-02950-x. PubMed
McClure JB, Lapham G Tobacco quitline engagement and outcomes among primary care patients reporting use of tobacco or dual tobacco and cannabis: An observational study 2020 Dec 3;42(4):417-422. doi: 10.1080/08897077.2020.1846665. Epub 2020-12-03. PubMed
Yeung K, Richards J, Goemer E, Lozano P, Lapham G, Williams E, Glass J, Lee A, Achtmeyer C, Caldeiro R, Parrish R, Bradley K Costs of using evidence-based implementation strategies for behavioral health integration in a large primary care system 2020 Dec;55(6):913-923. doi: 10.1111/1475-6773.13592. PubMed
Matson TE, Lapham GT, Bobb JF, Johnson E, Richards JE, Lee AK, Bradley KA, Glass JE Cannabis use, other drug use, and risk of subsequent acute care in primary care patients 2020 Nov;216:108227. doi: 10.1016/j.drugalcdep.2020.108227. Epub 2020-08-08. PubMed
Bradley KA, Lapham GT, Lee AK Screening for Drug Use in Primary Care: Practical Implications of the New USPSTF Recommendation 2020 Aug;180(8):1050-1051. doi: 10.1001/jamainternmed.2019.7335. PubMed
1 in 5 people who use cannabis daily at risk for moderate to severe use disorder.
New grant funds crucial work to test effectiveness of teen suicide prevention in primary care.
Five years and 8 scholars later, KPWHRI celebrates the impact of the CATALyST training program on early-career scientists.
A trial led by KPWHRI researchers found that adding nurse care managers helped more people get needed treatment.
New findings indicate medical cannabis use is associated with a lower risk of moderate to severe cannabis use disorder.
Medscape, Dec. 19, 2024